In my humble opinion, and sitting here at 4:15 am, I think
In my humble opinion, and sitting here at 4:15 am, I think the company will choose to uplist via the OTCMarkets program, and keep the M&A transaction on the back burner but not out of mind until the OTCMarkets offer is played out. The M&A transaction is not only expensive but it will take 9-11 months to complete the S-4 registration with the SEC. The iHub complainers will gripe about that too and make it sound like DECN is at fault that the SEC is methodical.
Uplisting for $12,500.00 ($2,500.00 application fee, and $10,000.00 listing fee) is a lot cheaper (and immediate if DECN is approved) than a merger with a non-shell shell, what with legal fees, SEC registration statement costs, stock distribution fees etc. But this is only my opinion.
I know that people on the iHub board will hate all of this because it could take away their pop-guns, so they will have to find something else to complain about -- and they will.
2
1
Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Key Opportunity for Coinbase Investors Investors holding Coinbase Global, Inc. (NASDAQ: COIN) securities may have a significant opportunity to participate in a class action lawsuit alleging serious violations of securities regulations. This opportunity arises from actions that took place during the specified Class Period. Investors are encouraged to evaluate their...
Continue Reading
BridGene Biosciences Raises Significant Funding BridGene Biosciences, Inc., renowned for its innovative approach in developing small molecule drugs, recently announced the completion of a substantial $28 million Series B+ financing round. This funding round was spearheaded by Bayland Capital, alongside notable contributions from GTJA Investment Group, Proxima Ventures,...
Continue Reading
NMD Pharma's Innovative Phase 2 Study with NMD670 NMD Pharma A/S, an ambitious clinical-stage biotech company, is making strides in the fight against neuromuscular diseases. They have officially begun their Phase 2a clinical trial of NMD670, a novel treatment aimed at addressing the challenges faced by patients with Charcot-Marie-Tooth (CMT) disease types 1 and 2. This...
Continue Reading
Introduction to Becker Milk Company's Financial Landscape Becker Milk Company Limited is making headlines with its financial results for the first half of its fiscal year. The latest report showcases their performance, reflecting on revenues and net income trends. Financial Highlights Overview Total revenues for the first six months reveal a detail-oriented insight into...
Continue Reading
Exciting New Flavor Launch from Mini Melts and 7-Eleven In an exciting collaboration, Mini Melts USA, a leader in premium beaded ice cream, has partnered with 7-Eleven, Inc. to introduce a new flavor reminiscent of the classic Blue Raspberry Slurpee. This innovative flavor captures the essence of the much-loved frozen drink, providing fans with a delightful and nostalgic...
Continue Reading
